← Leaderboards
Jennifer S Carew
Cleveland Clinic Lerner Com-Cwru
$2,669,041
Attributed
$4,153,748
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $744.6K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,153,748 · 4
By mechanism
R01$3,343,942 · 2
T32$551,465 · 1
R41$258,341 · 1
Top collaborators
- Steffan T Nawrocki5 shared
- Clara Curiel-Lewandrowski2 shared
- Gregory Charles Rogers2 shared
- Wei Wang1 shared
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Bin Zhang$6,324,932
- Vince Hascall$1,930,779
- Srinivasan Dasarathy$21,059,442
- Weifei Zhu$2,205,492
- Kyle Poulsen$2,013,633
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumor ProgressionOrganellesMouse ModelResponseAutophagocytosisStressPathway InteractionsDrug ResistancePathogenesisCell SurvivalResistanceTumorPlayApoptosisStandard Of CareNovel StrategiesMediatingClinical TrialsGeneticLysosomesMalignant - DescriptorIn VitroInhibitor
Grant awards (13)
Targeting Lysosomal Vulnerabilities in Renal Pathogenesis$480,833
R01 · FY2025 · CA
Targeting Lysosomal Vulnerabilities in Renal Pathogenesis$456,791
R01 · FY2024 · CA
Integrative Cancer Scholars Training Grant$287,821
T32 · FY2024 · CA · contact PI
Targeting Lysosomal Vulnerabilities in Renal Pathogenesis$471,216
R01 · FY2023 · CA
Integrative Cancer Scholars Training Grant$263,644
T32 · FY2023 · CA · contact PI
Targeting Lysosomal Vulnerabilities in Renal Pathogenesis$480,833
R01 · FY2022 · CA
Development of lysosome targeted therapeutics$258,341
R41 · FY2022 · CA · contact PI
Targeting NEDD8-Mediated Protein Turnover in AML$278,060
R01 · FY2019 · CA · contact PI
Targeting NEDD8-Mediated Protein Turnover in AML$286,661
R01 · FY2018 · CA · contact PI
Targeting NEDD8-Mediated Protein Turnover in AML$286,661
R01 · FY2017 · CA · contact PI
Targeting NEDD8-Mediated Protein Turnover in AML$205,853
R01 · FY2015 · CA · contact PI
Targeting NEDD8-Mediated Protein Turnover in AML$88,278
R01 · FY2015 · CA · contact PI
Targeting NEDD8-Mediated Protein Turnover in AML$308,756
R01 · FY2014 · CA · contact PI